Millipore Sigma Vibrant Logo
Attention: We have moved. EMD Millipore products are no longer available for purchase on emdmillipore.com.Learn More

IM29L Anti-PAI-1 (Ab-1) Mouse mAb (2)

Overview

Replacement Information

Key Specifications Table

Species ReactivityHostAntibody Type
HMMonoclonal Antibody

Products

Catalog NumberPackaging Qty/Pack
IM29L-100UG Plastic ampoule 100 μg
Description
OverviewRecognizes both active and latent forms of the ~50 kDa PAI-1 protein in conditioned media from dexamethasone-treated HT-1080 cells. Sold under license of U.S. Patent 5,422,245.
Catalogue NumberIM29L
Brand Family Calbiochem®
SynonymsAnti-Plasminogen Activator Inhibitor-1
References
ReferencesJanicke, F., et al. 1994. Cancer Research. 54, 2527.
Lawrence, D. A., et al. 1994. J. Biol. Chem. 269, 15223.
Nagayama, M., et al. 1994. Cancer 73, 1398.
Petersen, H., et al. 1994. Cancer Res. 54, 120.
Keijer, J., et al. 1991. Blood 78, 401.
Blasi, F. and Verde, P., 1990. in Seminars in Cancer Biol. Vol. 1, 153.
Declerck, P. J. and Collen, D., 1990. Thrombosis Res. Supplement X 3.
Nielsen, L. S., et al. 1986. Thrombosis and Haemostasis. 55, 206.
Product Information
DeclarationSold under license of U.S. Patent 5,422,245.
FormLyophilized
FormulationLyophilized from a volatile buffer, 100 µg BSA.
Positive controlConditioned media from dexamethasone-treated (1 µM) HT-1080 cells
PreservativeNone
Quality LevelMQ100
Applications
Application ReferencesImmunoprecipitation Keijer, J., et al. 1991. Blood 78, 401 Original Clone, Immunocytochemistry, Neutralization Studies Nielsen, L. S., et al. 1986. Thrombosis and Haemostasis. 55, 206.
Key Applications Immunoblotting (Western Blotting)
Immunocytochemistry
Immunoprecipitation
Neutralization Studies
Application NotesImmunoblotting (1 µg/ml)
Immunoprecipitation (see application references)
Immunocytochemistry (see application references
Neutralization Studies (see application references)
Application CommentsAntibody should be titrated for optimal results in individual systems.
Biological Information
Immunogenpartially purified PAI-1 from conditioned medium of dexamethasone-treated HT1080 human cells
ImmunogenHuman
Clone2
HostMouse
IsotypeIgG₁
Species Reactivity
  • Human
Antibody TypeMonoclonal Antibody
Physicochemical Information
Dimensions
Materials Information
Toxicological Information
Safety Information according to GHS
Safety Information
Product Usage Statements
Storage and Shipping Information
Ship Code Ambient Temperature Only
Toxicity Standard Handling
Storage +2°C to +8°C
Do not freeze Ok to freeze
Special InstructionsWe recommend resuspending the lyophilized antibody with sterile phosphate buffered saline (PBS), pH 7.4, or sterile 20 mM Tris-saline (20 mM Tris containing 0.15 M NaCl), pH 7.4, to yield a final concentration of 100 µg/ml. Lyophilized antibodies should be resuspended at 4°C with occasional gentle mixing for at least 2 h.
Packaging Information
Transport Information
Supplemental Information
Specifications
Global Trade Item Number
Catalog Number GTIN
IM29L-100UG 04055977220520

Documentation

Anti-PAI-1 (Ab-1) Mouse mAb (2) SDS

Title

Safety Data Sheet (SDS) 

Anti-PAI-1 (Ab-1) Mouse mAb (2) Certificates of Analysis

TitleLot Number
IM29L

References

Reference overview
Janicke, F., et al. 1994. Cancer Research. 54, 2527.
Lawrence, D. A., et al. 1994. J. Biol. Chem. 269, 15223.
Nagayama, M., et al. 1994. Cancer 73, 1398.
Petersen, H., et al. 1994. Cancer Res. 54, 120.
Keijer, J., et al. 1991. Blood 78, 401.
Blasi, F. and Verde, P., 1990. in Seminars in Cancer Biol. Vol. 1, 153.
Declerck, P. J. and Collen, D., 1990. Thrombosis Res. Supplement X 3.
Nielsen, L. S., et al. 1986. Thrombosis and Haemostasis. 55, 206.
Data Sheet

Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

Revision28-September-2007 JSW
SynonymsAnti-Plasminogen Activator Inhibitor-1
ApplicationImmunoblotting (1 µg/ml)
Immunoprecipitation (see application references)
Immunocytochemistry (see application references
Neutralization Studies (see application references)
DescriptionPurified mouse monoclonal antibody (see application references). Recognizes both active and latent forms of the ~50 kDa PAI-1 protein.
BackgroundPlasminogen activator inhibitor 1 (PAI-1) is a secreted glycoprotein of approximately 50 kDa, which functions as the primary regulator of uPA and tPA activity. PAI-1 and the related inhibitor, PAI-2, are members of the serine proteinase inhibitor (serpin) gene superfamily. PAI-1 is produced by a variety of cell types and is present in normal human plasma. It exists as two conformationally distinct forms, latent and active. The active form binds to uPA in a 1:1 complex resulting in the inhibition of proteolytic activity. Active PAI-1 rapidly converts to the latent form but can be stabilized in the active conformation by binding to the cell adhesion glycoprotein, vitronectin. Latent PAI-1 can be activated in vitro by exposure to denaturants such as SDS or guanidine. PAI-1 levels are increased in a number of disease states including coronary artery disease, venous thrombosis, obesity and various types of cancer. Recent studies indicate that elevated PAI-1 may be a useful prognostic marker for several types of cancers, particularly breast and lung.
HostMouse
Immunogen speciesHuman
Immunogenpartially purified PAI-1 from conditioned medium of dexamethasone-treated HT1080 human cells
Clone2
IsotypeIgG₁
Specieshuman
Positive controlConditioned media from dexamethasone-treated (1 µM) HT-1080 cells
FormLyophilized
FormulationLyophilized from a volatile buffer, 100 µg BSA.
PreservativeNone
CommentsAntibody should be titrated for optimal results in individual systems.
Storage +2°C to +8°C
Do Not Freeze Ok to freeze
Special InstructionsWe recommend resuspending the lyophilized antibody with sterile phosphate buffered saline (PBS), pH 7.4, or sterile 20 mM Tris-saline (20 mM Tris containing 0.15 M NaCl), pH 7.4, to yield a final concentration of 100 µg/ml. Lyophilized antibodies should be resuspended at 4°C with occasional gentle mixing for at least 2 h.
Toxicity Standard Handling
ReferencesJanicke, F., et al. 1994. Cancer Research. 54, 2527.
Lawrence, D. A., et al. 1994. J. Biol. Chem. 269, 15223.
Nagayama, M., et al. 1994. Cancer 73, 1398.
Petersen, H., et al. 1994. Cancer Res. 54, 120.
Keijer, J., et al. 1991. Blood 78, 401.
Blasi, F. and Verde, P., 1990. in Seminars in Cancer Biol. Vol. 1, 153.
Declerck, P. J. and Collen, D., 1990. Thrombosis Res. Supplement X 3.
Nielsen, L. S., et al. 1986. Thrombosis and Haemostasis. 55, 206.
Application referencesImmunoprecipitation Keijer, J., et al. 1991. Blood 78, 401 Original Clone, Immunocytochemistry, Neutralization Studies Nielsen, L. S., et al. 1986. Thrombosis and Haemostasis. 55, 206.